MediciNova, Inc. (MNOV) News
Filter MNOV News Items
MNOV News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
MNOV News Highlights
- For MNOV, its 30 day story count is now at 8.
- Over the past 21 days, the trend for MNOV's stories per day has been choppy and unclear. It has oscillated between 1 and 4.
- The most mentioned tickers in articles about MNOV are AUD and INST.
Latest MNOV News From Around the Web
Below are the latest news stories about MEDICINOVA INC that investors may wish to consider to help them evaluate MNOV as an investment opportunity.
MediciNova completes enrollment in mid-stage study of drug for alcohol use disorderMediciNova (MNOV) said that a phase 2b trial of MN-166 (ibudilast) to treat alcohol use disorder ((AUD)) has completed enrollment |
MediciNova Announces Completion of Enrollment in the Phase 2b Clinical Trial of MN 166 (ibudilast) in Alcohol Use DisorderLA JOLLA, Calif., Jan. 30, 2023 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that the Phase 2b clinical trial evaluating MN-166 (ibudilast) for the treatment of alcohol use disorder (AUD) has completed enrollment. This clinical trial was funded by the National Institute on Alcohol Abuse and Alcoholism (NIAAA). The NIAAA R01 research funding |
MediciNova Announces Completion of Enrollment in the Phase 2 Clinical Trial Evaluating MN-166 (ibudilast) for Treatment of Recurrent and Newly Diagnosed GlioblastomaPreliminary results will be presented at the 20th Annual World Congress of the Society for Brain Mapping and TherapeuticsLA JOLLA, Calif., Jan. 12, 2023 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that the Phase 2 clinical trial evaluating MN-166 (ibudilast) in recurrent and newly diagnosed glioblastoma conducted at Dana-Farber Cancer Inst |
MediciNova Receives a Notice of Allowance for a New Patent Covering MN-001 and MN-002 for the Treatment of Scleroderma and Systemic Sclerosis in CanadaLA JOLLA, Calif., Jan. 10, 2023 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced it has received a Notice of Allowance from the Canadian Intellectual Property Office for a pending patent application which covers MN-001 (tipelukast) and MN-002 (a major metabolite of MN-001) for the treatment of scleroderma and/or systemic sclerosis. Once issued, |
MediciNova to get patent in Brazil for cholesterol lowering therapyMediciNova (MNOV) said it received a notice of allowance from the Brazilian Patent and Trademark Office for a pending patent application which covers MN-001 (tipelukast) and MN-002… |
MediciNova Receives a Notice of Allowance for a New Patent Covering MN-001 and MN-002 for the Treatment of Hypertriglyceridemia, Hypercholesterolemia, and Hyperlipoproteinemia in BrazilLA JOLLA, Calif., Jan. 09, 2023 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced it has received a Notice of Allowance from the Brazilian Patent and Trademark Office for a pending patent application which covers MN-001 (tipelukast) and MN-002 (a major metabolite of MN-001) for the treatment of hypertriglyceridemia, hypercholesterolemia, and hype |
MediciNova to Meet with U.S. FDA to Discuss Clinical Development of a Parenteral Formulation of MN-166 (ibudilast)MN-166 (ibudilast) parenteral formulation showed a favorable safety and tolerability profile in healthy volunteersLA JOLLA, Calif., Jan. 05, 2023 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that a Phase I clinical trial to evaluate MN-166 (ibudilast) 10 mg intravenous (IV) infusion in healthy volunteers (HV) has been completed. The trial re |
MediciNova Announces Additional Positive Results Regarding the Effects of MN-001 (tipelukast) on Serum Lipid Panel in Type 2 Diabetes and NAFLD Patients Presented at IDF 2022 Congress, the Annual Meeting of the International Diabetes FederationLA JOLLA, Calif., Dec. 06, 2022 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that MediciNova’s Chief Medical Officer, Kazuko Matsuda, MD PhD MPH, presented positive results from a subgroup analysis of the completed Phase 2 clinical trial which evaluated MN-001 (tipelukast) for the treatment of hypertriglyceridemia at the International Diabet |
MediciNova Announces Positive Results from Secondary Analysis of Phase 2 Trial of MN-166 (ibudilast) Published in The American Journal of Drug and Alcohol AbuseLA JOLLA, Calif., Dec. 05, 2022 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that positive results from a secondary analysis of a Phase 2 trial of MN-166 (ibudilast) in alcohol use disorder (AUD) were published in The American Journal of Drug and Alcohol Abuse. The clinical trial was a collaborative effort between MediciNova and Dr. Lara Ray |
13 Best Biotech Penny Stocks To Buy NowIn this article, we will be taking a look at the 13 best biotech penny stocks to buy now. To skip our detailed analysis of these stocks, you can go directly to see the 5 Best Biotech Penny Stocks To Buy Now. Biotechnology is a sector that has long been contributing to the improvement of […] |